trial
as of 2026-07-01A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCTId NCT06887192
at a glance
Phase 2 · Recruiting
Enrollment 300 (estimated)
Sponsored by MapLight Therapeutics
Primary completion 2027-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Recruiting
Enrollment
300 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-08-15
Primary completion
2027-12
Eligibility
ALL · 55 Years · 90 Years
Interventions & indications
Drugs
Sponsors
MapLight TherapeuticsLead Sponsor
Investigators
1
MapLight TherapeuticsStudy Director
Sites
40 total
Phoenix, United StatesScottsdale, United StatesTucson, United StatesAnaheim, United StatesOrange, United StatesSan Diego, United StatesBoca Raton, United StatesDeerfield Beach, United StatesDoral, United StatesHomestead, United StatesMiami, United StatesMiami, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
300
Phase
PHASE2
Primary Completion Date
2027-12
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person